Phio Pharmaceuticals Corp Cash Flow Conversion Efficiency
Phio Pharmaceuticals Corp cash flow conversion efficiency. Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has a cash flow conversion efficiency ratio of -0.243x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.00 Million) by net assets ($16.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Phio Pharmaceuticals Corp (2011–2025)
Cash flow conversion efficiency of Phio Pharmaceuticals Corp from 2011 to 2025. This chart illustrates how Phio Pharmaceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Phio Pharmaceuticals Corp stock price for real-time trading data and today's change.
Phio Pharmaceuticals Corp Cash Flow Conversion Ratio Explained
Phio Pharmaceuticals Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Phio Pharmaceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their cash flow conversion efficiency. Also see market value of Phio Pharmaceuticals Corp for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VitzroSys Co Ltd
KQ:054220
|
0.090x |
|
Global Surfaces Limited
NSE:GSLSU
|
0.033x |
|
SAGTEC GLOBAL LIMITED Ordinary shares
NASDAQ:SAGT
|
0.281x |
|
DLB-Anlageservice AG
STU:DLB
|
N/A |
|
YOC AG
F:YOC
|
0.206x |
|
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
|
0.029x |
|
Kohinoor Foods Limited
NSE:KOHINOOR
|
-1.314x |
|
Dfcity Group Bhd
KLSE:5165
|
0.025x |
Annual Cash Flow Conversion Efficiency for Phio Pharmaceuticals Corp (2011–2025)
The table below shows the annual cash flow conversion efficiency of Phio Pharmaceuticals Corp from 2011 to 2025. Review Phio Pharmaceuticals Corp financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.15 Million | $-7.98 Million | -0.396x | +73.70% |
| 2024-12-31 | $4.72 Million | $-7.11 Million | -1.506x | -8.29% |
| 2023-12-31 | $7.73 Million | $-10.75 Million | -1.391x | -24.28% |
| 2022-12-31 | $10.84 Million | $-12.13 Million | -1.119x | -106.95% |
| 2021-12-31 | $21.93 Million | $-11.86 Million | -0.541x | +20.04% |
| 2020-12-31 | $13.02 Million | $-8.80 Million | -0.676x | +55.04% |
| 2019-12-31 | $5.75 Million | $-8.64 Million | -1.504x | -171.56% |
| 2018-12-31 | $13.58 Million | $-7.52 Million | -0.554x | +89.33% |
| 2017-12-31 | $1.83 Million | $-9.51 Million | -5.190x | -626.05% |
| 2016-12-31 | $10.86 Million | $-7.76 Million | -0.715x | +13.14% |
| 2015-12-31 | $8.89 Million | $-7.32 Million | -0.823x | +70.88% |
| 2014-12-31 | $2.75 Million | $-7.76 Million | -2.826x | -121.32% |
| 2013-12-31 | $4.94 Million | $-6.31 Million | -1.277x | -247.33% |
| 2012-12-31 | $-5.84 Million | $-5.06 Million | 0.867x | -94.91% |
| 2011-12-31 | $-587.00K | $-9.99 Million | 17.017x | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more